Christopher Durant Turner Nuvalent, Inc. (NUVL) insider trading activity

Christopher Durant Turner is Chief Medical Officer of Nuvalent, Inc.. Currently has a direct ownership of 72,630 shares of NUVL, which is worth approximately $7.01 Million. The most recent transaction as insider was on Jan 07, 2026, when has been sold 17,500 shares (Class A Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 72.6K

16.12% 3M change

16.12% 12M change

Total Value Held $7.01 Million

Christopher Durant Turner Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 07 2026	BUY Grant, award, or other acquisition	-	17,500 Added 19.42%	72,630 Class A Common Stock
Jan 06 2026	SELL Open market or private sale	$310,115 $97.49 p/Share	3,181 Reduced 5.46%	55,130 Class A Common Stock
Jan 05 2026	SELL Open market or private sale	$412,374 $97.35 p/Share	4,236 Reduced 6.77%	58,311 Class A Common Stock
Jan 06 2025	SELL Open market or private sale	$318,790 $79.38 p/Share	4,016 Reduced 6.03%	62,547 Class A Common Stock
Jan 06 2025	BUY Grant, award, or other acquisition	-	18,750 Added 21.98%	66,563 Class A Common Stock
Jan 05 2024	BUY Grant, award, or other acquisition	-	33,300 Added 41.05%	47,813 Class A Common Stock
Oct 04 2023	SELL Open market or private sale	$439,804 $55.01 p/Share	7,995 Reduced 35.52%	14,513 Class A Common Stock

Oct 04 2023	BUY Exercise of conversion of derivative security	$55,085 $6.89 p/Share	7,995 Added 26.21%	22,508 Class A Common Stock
Jul 28 2023	SELL Open market or private sale	$130,398 $48.93 p/Share	2,665 Reduced 15.51%	14,513 Class A Common Stock
Jul 28 2023	BUY Exercise of conversion of derivative security	$18,361 $6.89 p/Share	2,665 Added 13.43%	17,178 Class A Common Stock
Jul 26 2023	SELL Open market or private sale	$110,800 $46.85 p/Share	2,365 Reduced 14.01%	14,513 Class A Common Stock
Jul 26 2023	BUY Exercise of conversion of derivative security	$16,294 $6.89 p/Share	2,365 Added 12.29%	16,878 Class A Common Stock
Jul 24 2023	SELL Open market or private sale	$9,364 $46.82 p/Share	200 Reduced 1.36%	14,513 Class A Common Stock
Jul 24 2023	BUY Exercise of conversion of derivative security	$1,378 $6.89 p/Share	200 Added 1.34%	14,713 Class A Common Stock
Jul 20 2023	SELL Open market or private sale	$4,680 $46.8 p/Share	100 Reduced 0.68%	14,513 Class A Common Stock
Jul 20 2023	BUY Exercise of conversion of derivative security	$689 $6.89 p/Share	100 Added 0.68%	14,613 Class A Common Stock
Jun 05 2023	SELL Open market or private sale	$459,142 $44.86 p/Share	10,235 Reduced 41.36%	14,513 Class A Common Stock
Jun 05 2023	BUY Exercise of conversion of derivative security	$70,519 $6.89 p/Share	10,235 Added 29.26%	24,748 Class A Common Stock
May 17 2022	BUY Exercise of conversion of derivative security	$99,995 $6.89 p/Share	14,513 Added 50.0%	14,513 Class A Common Stock

CDT

Christopher Durant Turner

Chief Medical Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NUVL shares.

Notify only if

Value

Insider Trading

Get notified when an Nuvalent, Inc. insider buys or sells NUVL shares.

Notify only if

Operation

Value

Type

News

Receive news related to Nuvalent, Inc.

Track Activities on NUVL

Account